The current diagnostic framework for clinical AD and other neurological disorders fails to capture this biological diversity. The limited number of clinically established biomarkers stands to hinder advancements in diagnostic subtyping, disease monitoring, and therapeutic development. Approaching such a biologically heterogenous disease as a single entity in clinical trials may account for the many drug failures. A systems-based approach to biomarker discovery, as championed by the AMP-AD initiative, is growing in popularity among neurodegenerative disorders. The Seyfried Lab aims to translate the network AD brain proteome into systems-based, physiologically diverse, multiplex biomarker assays capable of advancing our clinical framework of disease.